Citius Oncology Inc
CTOR
NASDAQ
Biotechnology
$0.91
USD
+0.08 (+10.04%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $68.57M
Volume 226.2K
Revenue
$5.61M
TTM
— YoY
Gross Margin
80%
TTM
— YoY
Net Income
$-42.51M
TTM
— YoY
Operating Cash Flow
$-16.68M
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 3.9 | 1.7 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.8 | 0.3 |
Gross Profit | 0.0 | 0.0 | 0.0 | 3.2 | 1.3 |
Selling, General & Administrative | 2.2 | 4.0 | 3.6 | 6.8 | 23.6 |
Other Operating Expenses | 2.1 | 0.0 | 0.0 | 0.0 | 3.5 |
Total Operating Expenses | 7.5 | 4.9 | 4.7 | 8.4 | 30.0 |
Operating Income | -7.5 | -4.9 | -4.7 | -5.3 | -28.6 |
EBITDA | -7.5 | -4.9 | -4.7 | -4.7 | -29.2 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 1.8 |
Total Other Income / Expense | 0.0 | -0.2 | -0.0 | -0.0 | 1.8 |
Income Before Income Taxes | -7.5 | -5.1 | -4.7 | -5.3 | -26.8 |
Income Taxes | 0.3 | 0.3 | 0.3 | 0.3 | -0.2 |
Net Income | -7.7 | -5.4 | -5.0 | -5.5 | -26.6 |
Consolidated Net Income / Loss | -7.7 | -5.4 | -5.0 | -5.5 | -26.6 |
Net Income Attributable to Common Shareholders | -7.7 | -5.4 | -5.0 | -5.5 | -26.6 |
Basic EPS | -$0.11 | -$0.08 | -$0.06 | -$0.06 | -$0.27 |
Diluted EPS | -$0.11 | -$0.08 | -$0.06 | -$0.06 | -$0.27 |
Basic Shares Outstanding | 71.6M | 71.6M | 78.4M | 87.5M | 100.0M |
Diluted Shares Outstanding | 71.6M | 71.6M | 78.4M | 87.5M | 100.0M |